ELOX · Nasdaq · ·
Next earnings: November 10, 2026
$15.21-1.1%Sep 29 close
Eloxx Pharmaceuticals, Inc. is scheduled to report next on November 10, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2012, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2012 | 3 months toDec 31, 2011 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $200K | -100.00% |
| Profit | -$4.5M | -$2.9M | -55.72% |
| Profit per share | -$0.66 | -$1.31 | +49.62% |
| Free Cash Flow | -$3.5M | -$7M | +50.67% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The second quarter was transformational for Eloxx. Our public offering, with gross proceeds of $66.0 million, together with our uplisting to the Nasdaq Capital Market, has meaningfully strengthened our balance sheet and provides the resources to advance exaluren across our rare kidney disease programs,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) is a clinical-stage biopharmaceutical company developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins. Eloxx’s lead product candidate, exaluren, is being developed for the treatment of rare kidney diseases, including nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD). Eloxx has also exclusively licensed its product candidate, ZKN-013, to Almirall, S.A., which is developing it for the treatment of rare dermatological diseases associated with nonsense mutations.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Eloxx Pharmaceuticals, Inc.’s Item 2.02 8-K filed August 11, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Eloxx Pharmaceuticals, Inc. has no earnings call transcript available.